Loading clinical trials...
Loading clinical trials...
A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen
Conditions
Interventions
ZD4054
Pemetrexed
+1 more
Locations
13
Bulgaria
research Site
Pleven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Jičín, Czechia
Research Site
Prague, Czechia
Research Site
Cedex, France
Start Date
August 1, 2008
Primary Completion Date
January 1, 2010
Completion Date
January 1, 2010
Last Updated
June 6, 2012
NCT05198830
NCT06498635
NCT06066138
NCT07486219
NCT07336732
NCT05692635
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions